Why the study?
Does rilmenidine and its combination with amlodipine improve plasma glucose, lipids, and body weight in the ALTAIR study population?
Does rilmenidine and its combination with amlodipine improve plasma glucose, lipids, and body weight in the ALTAIR study population?
Rilmenidine therapy improves metabolic parameters such as glucose, lipids, and body weight, particularly in obese and diabetic patients.
Observed metabolic benefits with rilmenidine should not change practice; hypothesis-generating and leaves causal effects on outcomes open.
The aim of the study was to evaluate effects of rilmenidine and its combination with amlodipine on plasma glucose and lipids as well as body weight in ALTAIR study population. Rilmenidine therapy resulted in several positive metabolic effects: decrease in glucose, total cholesterol and triglyceride levels as well as decrease in body weight. The most prominent metabolic effects were shown fro patients with concomitant obesity and in diabetic subpopulation. In conclusion, analysis of ALTAIR data indicates that Imidazoline agonists, in particular rilmenidine, can be considered the first drug choice in patients with metabolic abnormalities.
No takes yet. Share an insight, caveat, or question.
Conrady et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: